Ultra-Low-Dose Induction Protocol Opens OIT Path for Children With Severe Nut Allergies

An observational cohort study published in 2026 indicates that an ultra-low-dose induction strategy can make conventional oral immunotherapy (OIT) viable for children whose severe peanut or walnut allergies previously prevented treatment initiation. Researchers evaluated 21 pediatric patients aged over three years between 2021 and 2024 who faced severe clinical barriers, including histories of anaphylaxis, Grade 2 or higher allergic reactions, and extreme sensitivity to trace allergen amounts.

According to PubMed Central (PMC) / NIH, studies have generally reported peanut allergy prevalence rates between 1% and 2% in Western nations.

Protocol Design and Transition Milestones

The multicenter investigation assigned participants to peanut or walnut allergy cohorts, establishing individualized starting doses via serial five-fold dilutions of allergen extracts. Children ingested these diluted extracts twice daily for a month, while subsequent monthly clinical evaluations progressively raised doses through increased drop counts and more concentrated extract formulations, provided the children maintained clinical tolerance.

Following this multi-month induction phase, every participant in the peanut allergy group and 90.9 percent of the walnut cohort successfully progressed to conventional OIT regimens, tolerating milligram-level protein powder ingestion. The median timeframe required to achieve this transition reached 16 months for peanut-allergic children and eight months for those with walnut allergies.

Safety Profile and Daily Living Outcomes

During home-based drop maintenance, adverse events proved extremely infrequent, registering at 0.02 percent of administered doses for peanuts and 0.09 percent for walnuts. These recorded episodes remained primarily mild to moderate in severity, and no patient required adrenaline administration at any point throughout the observation period.

According to European Medical Journal (EMJ), for Evolution of food allergy oral immunotherapy, Extremely low reaction thresholds and histories of severe reactions prevented patients from initiating or progressing with conventional OIT.

Beyond building physiological tolerance during clinical challenges, researchers observed that 30 percent of children with peanut allergies and 27.3 percent of those with walnut allergies successfully incorporated commercially packaged products containing their respective allergens into their diets. Investigators noted that beyond elevating the reactive threshold, the protocol may help alleviate daily psychological anxiety surrounding accidental exposure.

However, authors of the study emphasized important methodological caveats. The absence of a randomized control group and the utilization of non-standardized allergen extracts mean further clinical trials are necessary to substantiate these findings.